Lebrikizumab Confirms a Consistent Safety Profile in Adults and Adolescents With Moderate-to-Severe Atopic Dermatitis: ​ Data From 11 Trials With Over 3000 Patient-Years of Exposure. J of Skin [Internet]. 2025 Jan. 13 [cited 2025 Apr. 13];9(1):s511. Available from: https://skin.dermsquared.com/skin/article/view/3152